Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70


Cost-Effectiveness between Double and Single Fecal Immunochemical Test(s) in a Mass Colorectal Cancer Screening.

Cai SR, Zhu HH, Huang YQ, Li QL, Ma XY, Zhang SZ, Zheng S.

Biomed Res Int. 2016;2016:6830713. doi: 10.1155/2016/6830713. Epub 2016 Apr 7.


New era of colorectal cancer screening.

El Zoghbi M, Cummings LC.

World J Gastrointest Endosc. 2016 Mar 10;8(5):252-8. doi: 10.4253/wjge.v8.i5.252. Review.


Recommendations on screening for colorectal cancer in primary care.

Canadian Task Force on Preventive Health Care, Bacchus CM, Dunfield L, Gorber SC, Holmes NM, Birtwhistle R, Dickinson JA, Lewin G, Singh H, Klarenbach S, Mai V, Tonelli M.

CMAJ. 2016 Mar 15;188(5):340-8. doi: 10.1503/cmaj.151125. Epub 2016 Feb 22. No abstract available.


Advances in Fecal Tests for Colorectal Cancer Screening.

Schreuders EH, Grobbee EJ, Spaander MC, Kuipers EJ.

Curr Treat Options Gastroenterol. 2016 Mar;14(1):152-62. doi: 10.1007/s11938-016-0076-0.


Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study.

Jensen CD, Corley DA, Quinn VP, Doubeni CA, Zauber AG, Lee JK, Zhao WK, Marks AR, Schottinger JE, Ghai NR, Lee AT, Contreras R, Klabunde CN, Quesenberry CP, Levin TR, Mysliwiec PA.

Ann Intern Med. 2016 Apr 5;164(7):456-63. doi: 10.7326/M15-0983. Epub 2016 Jan 26.


A Blood Test for Methylated BCAT1 and IKZF1 vs. a Fecal Immunochemical Test for Detection of Colorectal Neoplasia.

Symonds EL, Pedersen SK, Baker RT, Murray DH, Gaur S, Cole SR, Gopalsamy G, Mangira D, LaPointe LC, Young GP.

Clin Transl Gastroenterol. 2016 Jan 14;7:e137. doi: 10.1038/ctg.2015.67.


Consensus on the Prevention, Screening, Early Diagnosis and Treatment of Colorectal Tumors in China: Chinese Society of Gastroenterology, October 14-15, 2011, Shanghai, China.

Fang JY, Zheng S, Jiang B, Lai MD, Fang DC, Han Y, Sheng QJ, Li JN, Chen YX, Gao QY.

Gastrointest Tumors. 2014 Jun;1(2):53-75. doi: 10.1159/000362585. Epub 2014 May 9.


Timing and Risk Factors for a Positive Fecal Immunochemical Test in Subsequent Screening for Colorectal Neoplasms.

Chiang TH, Lee YC, Liao WC, Chung JH, Chiu HM, Tu CH, Chen SC, Wu MS.

PLoS One. 2015 Sep 2;10(9):e0136890. doi: 10.1371/journal.pone.0136890. eCollection 2015.


Rectal Optical Markers for In Vivo Risk Stratification of Premalignant Colorectal Lesions.

Radosevich AJ, Mutyal NN, Eshein A, Nguyen TQ, Gould B, Rogers JD, Goldberg MJ, Bianchi LK, Yen EF, Konda V, Rex DK, Van Dam J, Backman V, Roy HK.

Clin Cancer Res. 2015 Oct 1;21(19):4347-55. doi: 10.1158/1078-0432.CCR-15-0136. Epub 2015 May 19.


Using the Cancer Risk Management Model to evaluate colorectal cancer screening options for Canada.

Coldman AJ, Phillips N, Brisson J, Flanagan W, Wolfson M, Nadeau C, Fitzgerald N, Miller AB.

Curr Oncol. 2015 Apr;22(2):e41-50. doi: 10.3747/co.22.2013.


Comparison of patient preferences for fecal immunochemical test or colonoscopy using the analytic hierarchy process.

Xu Y, Levy BT, Daly JM, Bergus GR, Dunkelberg JC.

BMC Health Serv Res. 2015 Apr 23;15:175. doi: 10.1186/s12913-015-0841-0.


Improving uptake of screening for colorectal cancer: a study on invitation strategies and different test kit use.

Santare D, Kojalo I, Huttunen T, Rikacovs S, Rucevskis P, Boka V, Leja M.

Eur J Gastroenterol Hepatol. 2015 May;27(5):536-43. doi: 10.1097/MEG.0000000000000314.


Blood-based protein biomarker panel for the detection of colorectal cancer.

Fung KY, Tabor B, Buckley MJ, Priebe IK, Purins L, Pompeia C, Brierley GV, Lockett T, Gibbs P, Tie J, McMurrick P, Moore J, Ruszkiewicz A, Nice E, Adams TE, Burgess A, Cosgrove LJ.

PLoS One. 2015 Mar 20;10(3):e0120425. doi: 10.1371/journal.pone.0120425. eCollection 2015.


The impact of screening on colorectal cancer mortality and incidence: has it really made a difference?

Zauber AG.

Dig Dis Sci. 2015 Mar;60(3):681-91. doi: 10.1007/s10620-015-3600-5. Epub 2015 Mar 5. Review.


Prospective cross-sectional study on faecal immunochemical tests: sex specific cut-off values to obtain equal sensitivity for colorectal cancer?

van Turenhout ST, Oort FA, van der Hulst RW, Visscher AP, Terhaar sive Droste JS, Scholten P, Bouman AA, Meijer GA, Mulder CJ, van Rossum LG, Coupé VM.

BMC Gastroenterol. 2014 Dec 21;14:217. doi: 10.1186/s12876-014-0217-7.


Clinical application of DNA ploidy to cervical cancer screening: A review.

Garner D.

World J Clin Oncol. 2014 Dec 10;5(5):931-65. doi: 10.5306/wjco.v5.i5.931. Review.


Advances in Fecal Occult Blood Tests: the FIT revolution.

Young GP, Symonds EL, Allison JE, Cole SR, Fraser CG, Halloran SP, Kuipers EJ, Seaman HE.

Dig Dis Sci. 2015 Mar;60(3):609-22. doi: 10.1007/s10620-014-3445-3. Epub 2014 Dec 10. Review.


Diagnostic accuracy of fecal immunochemical test in average- and familial-risk colorectal cancer screening.

Cubiella J, Castro I, Hernandez V, González-Mao C, Rivera C, Iglesias F, Alves MT, Cid L, Soto S, De-Castro L, Vega P, Hermo JA, Macenlle R, Martínez A, Estevez P, Cid E, Herreros-Villanueva M, Portillo I, Bujanda L, Fernández-Seara J; COLONPREV study investigators.

United European Gastroenterol J. 2014 Dec;2(6):522-9. doi: 10.1177/2050640614553285.


Potential of fecal microbiota for early-stage detection of colorectal cancer.

Zeller G, Tap J, Voigt AY, Sunagawa S, Kultima JR, Costea PI, Amiot A, Böhm J, Brunetti F, Habermann N, Hercog R, Koch M, Luciani A, Mende DR, Schneider MA, Schrotz-King P, Tournigand C, Tran Van Nhieu J, Yamada T, Zimmermann J, Benes V, Kloor M, Ulrich CM, von Knebel Doeberitz M, Sobhani I, Bork P.

Mol Syst Biol. 2014 Nov 28;10:766. doi: 10.15252/msb.20145645.


The effect of changing stool collection processes on compliance in nationwide organized screening using a fecal occult blood test (FOBT) in Korea: study protocol for a randomized controlled trial.

Shin HY, Suh M, Baik HW, Choi KS, Park B, Jun JK, Lee CW, Oh JH, Lee YK, Han DS, Lee DH.

Trials. 2014 Nov 26;15:461. doi: 10.1186/1745-6215-15-461.

Items per page

Supplemental Content

Write to the Help Desk